USCOM LIMITED — AGM Information 2025

Nov 26, 2025

RAP©️

==> picture [422 x 175] intentionally omitted <==

FY25 AGM Presentation

ASX: UCM

==> picture [169 x 123] intentionally omitted <==

• Resolutions & Voting

• Overview, products and markets

• Milestones

• FY2025 Results

• FY2026 Drivers

Prof.Rob Phillips Founder and Chairman, Uscom Limited

Nov 27, 2025

Overview

USCOM Vision

World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijing, Budapest, London Delaware

• Cardiovascular and pulmonary devices

• Expanding product portfolio

• Digital technology

• Wireless connectivity

• Flagship science and technology in prestige cardiovascular and pulmonary sector.

• Multiple products with global regulatory

• Addressing diseases responsible for >75% of all mortality

• Foxconn manufacturing partnership to underwrite growth

• Chinese Foxconn domestic manufacturing, into global distribution

• High margin and >75 IP submissions

~ 2000 > 75 IP > 20 years in Sales into 52 > 1,200 peer Installed submissions business countries publications USCOM 1A IP submissions >$40m total receipts Global clinical International peer USCOM 1A units protecting Uscom over 10 years adoption across reviewed technology installed globally many applications publications

==> picture [371 x 376] intentionally omitted <==

"Medical innovations for the World"

==> picture [8 x 5] intentionally omitted <==

5

==> picture [131 x 24] intentionally omitted <==

----- Start of picture text -----

Product
----- End of picture text -----

Non-invasive Medical Devices Improving Clinical Care And Patient Outcomes

==> picture [17 x 11] intentionally omitted <==

USCOM 1A

==> picture [35 x 10] intentionally omitted <==

Non-invasive Hemodynamic Monitor

==> picture [134 x 135] intentionally omitted <==

Flagship digital Doppler device enabling real-time, non-invasive hemodynamic monitoring

• Provider of high-fidelity measurement and trending information on cardiovascular performance

• More accurate and cost-effective than invasive catheter-based hemodynamic monitoring

• Early detection a n d precision management of heart failure, systemic infections (e.g. sepsis, dengue), fluid guidance and hypertension

• Expanding clinical applications in preeclampsia and burn management

==> picture [66 x 40] intentionally omitted <==

Central BP and Pulse Wave Analysis Monitor

==> picture [199 x 123] intentionally omitted <==

Patented technology measuring central aortic pressure via upper arm cuff

• Emerging standard of care in hypertension, heart failure and vascular health

• Replaces conventional and widespread subsystolic BP monitors (only 20% effective)

• BP+Home specialised device for home care hypertensionand heart failure monitoring with digital cloud-based connectivity

• In International Space station and European space programme

• Recent China NMPA approval

Ultrasonic Spirometer

==> picture [215 x 116] intentionally omitted <==

Digital ultrasonic spirometers for remote and in-clinicpulmonary monitoring

• Digital ultrasonic accuracy for pre/post-surgical monitoring of pulmonary functions and selfmanagement

• Equipped with autodiagnostics, digital connectivity, and real-time patient feedback

• Real time lung function data for diagnosis and monitoring of asthma, COPD, occupational lung disease and pulmonary fibrosis

• Recent China NMPA approval

==> picture [8 x 5] intentionally omitted <==

6

==> picture [131 x 24] intentionally omitted <==

----- Start of picture text -----

Milestones
----- End of picture text -----

USCOM’s Journey

==> picture [66 x 80] intentionally omitted <==

1999		2015	2022 2025
• Uscom Limited established		• Acquired Thor Laboratories to	• Entered strategic partnership with • Uscom became
		transform toSpiroSonic	Foxconn member of AustCha
2003			• Received Brea
• ASX listed – UCM 2010 • Successfully developed and clinically validatedUSCOM1A • Achieved sales approvals in the US, China, EU, Canada, and Asia-Pacific		2017 • Critical USCOM evidence for preeclampsia 2018 • Uscom Chinaestablished as National High Tech Enterprise by China Ministry of Science and Technology	For Investors Uscom’s innovative product 2023 • Domestic manufacturing of USCOM devices approved in China 2024 • BP+ demonstrated as World Leading BP Monitor by ARTERY Validation • On going discussions withChina Technology Awar Premier Health Grou • Established Uscom Facility atWest Chin
2013 • Acquired Pulsecor to transform to BP+technologies		2020 • Recommended inCovid 19 treatment • USCOM1A in international Sepsis Guidelines for children	line, recurring revenue potential, and alignment with global healthcare trends make it a compelling growth Resources Healthcare • Signed strategic partnership with Sinopharm

• Uscom became corporate member of AustCham China.

• • Received Break-through Technology Award from Premier Health Group

• • Established Uscom Training Facility at West China hospital

==> picture [8 x 5] intentionally omitted <==

"Medical innovations for the World"

7

==> picture [131 x 24] intentionally omitted <==

----- Start of picture text -----

Milestones
----- End of picture text -----

Global Footprint

==> picture [903 x 381] intentionally omitted <==

----- Start of picture text -----

Belgium – Mons
Université de Mons
Slovenjia – Lubiana
University Medical Centre Poland – Lodz Chongqing
PERIN Polish Mother’s Chongqing Beijing
Chicago Memorial Hospital Children's Hospital Fuwai Cardiovascular Hospital
Italy – Roma Uscom Training and
Illinois Children’s Hospital Policlinico Casilino Hospital Chekz Rep – Praga Jinan Teaching Centre
Italy – Padova Charles University Shandong Provincial Hospital
Policlinico - TIN Chengdu
Pittsburgh
UPMC Children’s Hospital IRCCS Policlinico – Clinica Italy – Milano Women’s and Children’s West China Shanghai
Cincinnatti Pittsburgh Mangiagalli Hungary – Budapest Hospital Shenzhen Children’s Hospital of Shanghai
Szent Istvan & Szenr Laszlo Shenzhen Children’s
Cincinnatti Children’s Houston EItaly – Milano
Hospital Hospital Shanghai
HospitaL Texas Children’s Hospital Policlinico – Clinica De Marchi - PS Switzerland - Geneva FuDan University HuaShan Hospital
Hopiteaux Universitaire de
Italy – Parma & Firenze Geneve Fujian
A.O.U. Parma & A.O.U. Careggi – Austria – Vienna Guangzhou Fujian Maternal and Children’s Hospital
Materno Infantile
LA St Louis Medical University Guangdong
Barnes Jewish Hospital Italy – Trieste General Hospital
Children’s Hospital of Los Italy – Faenza
Angeles New York Ospedale Burlo Garofolo Ospedale Civile – PS – Chengdu Xiamen
Med Urgenza Xiamen University No1 Hospital
Mount Sinai Hospital New York Italy – Roma Italy - – Vienezia West China Hospital Jakarta
Policlinico Gemelli - TIP Medical University Cipto Mangankusumo Hospital Brisbane
Prince Charles Hospital
Maine Belgium – Genk
Italy – Monza
Maine General Hospital Ziekenhuis Oost-
Jackson Ospedale San Limburg Hospital
Gerardo - TIN
University of Miami Singapore – Sydney
Lithuania – Vilnius S Africa Capetown - KK Women’s and St George Hospital
Santariskiu University Children’s
UCT University of Capetown
Brazil – Sao Paulo
Netherlands – Maastericht
Instituta da Crianca,
Maastricht University S Africa – Durban Adelaide
University Sao Paulo
Hospital Ethekwinin Hospital and Heart Lyell McEwin Hospital
Centre
----- End of picture text -----

Uscom - In The World’s Best Hospitals

==> picture [8 x 5] intentionally omitted <==

8

Milestones

Operational Milestones

==> picture [462 x 262] intentionally omitted <==

==> picture [48 x 58] intentionally omitted <==

Sinopharm Partnership

• SinoPharm is one of China’s largest medical device distributors and has signed a cooperative agreement with Uscom China for development of new marketing and sale initiatives. This collaboration will allow SinoPharm to diversify from principally pharmaceuticals to medical devices while providing Uscom access to SinoPharm’s distribution and sales network being the third largest in the world.

Huaxi and University of Queensland

• Huaxi is China’s largest and no 1 Hospital serving over 9,000 beds and providing >8M consultations and 2M telemetric consultations. Prof Phillips has opened the doors of collaboration between Huaxi and the University of Queensland and has now been appointed as a visiting Professor to Huaxi, one of the few foreigners appointed to the Hospital.

Prime Ministerial China Medtech Visit

• Prime Minister Anthony Albanese visited China to promote the new revitalized Australia and Chinese engagement with a focus on three major sectors; resources, food and agriculture and Medtech. Uscom featured at the Medtech meeting and made representation to the Prime Minister.

==> picture [8 x 5] intentionally omitted <==

9

FY25 Results

FY25 Results - Globally

UCM Total Receipts Trend FY12 – FY26*

1 9 %

2 9 % CAGR* (14yrs) CAGR (8yrs Pre-covid)

==> picture [49 x 47] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

==> picture [39 x 39] intentionally omitted <==

$2.58 million $3.16 million 25% Sale of Products Total Revenue

Down in Revenue

Building the future

Results

• Sale of products $2.58m

• Revenue from ordinary activities down 25%, Sales declined in all regions except SE Asia , Cash on Hand $967k

• 29% CAGR over 8yr excluding 3 years of COVID and Russian war, plus 1 year of tariffs.

• 19% CAGR over 14yr using FY26 mid sales forecasts and including 3 years of COVID and Russian war, plus 1 year of tariffs.

==> picture [8 x 5] intentionally omitted <==

10

FY25 Results

FY25 Results - Regionally

Uscom Total Revenue by Region

==> picture [286 x 206] intentionally omitted <==

----- Start of picture text -----

19%
Asia
8% 47% Europe
US/Other
Australia
26%
----- End of picture text -----

• Global platform for growth

• Hedged for currency and shifting geopolitics

==> picture [463 x 273] intentionally omitted <==

• Global reporting, tax, transfer pricing and auditing

==> picture [8 x 5] intentionally omitted <==

11

FY26 Drivers

FY26 Drivers

==> picture [27 x 26] intentionally omitted <==

==> picture [27 x 26] intentionally omitted <==

==> picture [27 x 26] intentionally omitted <==

==> picture [27 x 26] intentionally omitted <==

==> picture [27 x 26] intentionally omitted <==

==> picture [27 x 26] intentionally omitted <==

• China:

• Uscom’s partnership with Foxconn is expanding into a new high technology Medtech centre in Daxing, an outer suburb of Beijing. Eventually, this centre will provide supply chain and manufacturing capabilities for all Uscom devices worldwide.

• The Uscom–SinoPharm partnership has progressed to the training stage and is expected to begin clinical trials over the next six months, but this penetration has been slowed due to national market uncertainty.

• SE Asia: Uscom is currently in discussion with the Indonesian Government for the national roll-out of USCOM 1A devices, which will be implemented in approximately 40 paediatric centres across Indonesia, and clinicians will be trained on the use of USCOM 1A’s, particularly for the delivery of critical care to children with Dengue sepsis.

• US: Our new partnerships with Premier Health represent a preferred path to market, and Uscom is planning to support expansion of this major US hospital group to optimise delivery of Uscom technologies into the large US market. Recent legislative developments in the US have further complicated the regulatory and purchasing systems in the US.

• Europe: Uscom is strengthening its footprint across Europe, with a strong focus on maternal health and advancing solutions for preeclampsia—one of the leading causes of maternal and fatal complications.

==> picture [8 x 5] intentionally omitted <==

12

Conclusion

Conclusion

FY25 was a year of adaptation for Uscom Limited.

==> picture [66 x 80] intentionally omitted <==

Navigated unpredictable global geopolitics. Trade wars, tariff wars, currency wars, and military conflicts across multiple continents and markets.

Global team has maintained sales focus in preparation for the inevitable recovery

We have developed our devices and planned new technologies to create a new medical technology and revenue platforms for our future.

While the FY25 decrease in sales was disappointing, Uscom devices continue to save lives, change medical practice, and improve our understanding of clinical medicine in a difficult commercial environment, and we can all be proud of that.

Everyone within Uscom, including each investor, is a part of our team and supports our mission to improve global healthcare.

==> picture [156 x 70] intentionally omitted <==

Professor Rob Phillips Uscom Chairman and CEO

==> picture [8 x 5] intentionally omitted <==

13

==> picture [960 x 540] intentionally omitted <==

----- Start of picture text -----

Corporate Social Responsibility
Australian Wildlife Conservancy (AWC)
Australia is the extinction capital of the world
In 15 years the list of threatened species has increased by 36%
87% of Australia’s mammals,
93% of our reptiles,
94% of our frogs,
and 45% of our bird species
are unique to Australia
www.australianwildlife.org
Saving Australia’s animals and plants Rob Phillips personally contributes to AWC on behalf of Uscom
----- End of picture text -----

RAP©️

==> picture [422 x 175] intentionally omitted <==

FY25 AGM Presentation

ASX: UCM

==> picture [169 x 123] intentionally omitted <==

• Resolutions & Voting

• Overview, products and markets

• Milestones

• FY2025 Results

• FY2026 Drivers

Prof.Rob Phillips Founder and Chairman, Uscom Limited

Nov 27, 2025